- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05151133
Clinical Study of Allergic Rhinitis Therapy by Stem Cells
Clinical Study of Moderate to Severe Persistent Allergic Rhinitis Therapy by Human Umbilical Cord Mesenchymal Stem Cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Allergic rhinitis (AR), is a noninfectious inflammatory disease of nasal mucosa mediated by immunoglobulin E (IgE) antibody and involved in a variety of immune active cells and cytokines after the atopic body is exposed to allergens. The incidence of allergic rhinitis increases as people's living standards improves. It is estimated that about 1.4 billion people worldwide have been affected by the disease. Some patients with moderate to severe AR have no improvement in symptoms after drug treatment, which continues to affect daily life and work. Therefore, these patients urgently needs a new, minimally invasive, effective and simple treatment. Mesenchymal Stem Cells (MSCs) are pluripotent stem cells derived from the mesoderm, which can differentiate into bone, cartilage, fat and other cells. MSCs can also secrete a variety of bioactive molecules, which have the effects of regulating immunity and anti-inflammatory. Based on its immunomodulatory effect, MSCs is gradually becoming a new star in the treatment of allergic diseases. In pre-clinical studies on the treatment of AR, MSCs have shown good therapeutic effect in the treatment of allergic rhinitis.
This study is a prospective, open, single-center clinical study. Participants were recruited into three different dose groups. The cohort size of each dose group was 6 participants. The subjects of each group each will receive one course of treatment with a single injection. Subjects of group 1 will receive 0.5×10^6 cells/kg, with a total volume of 100 ml UCMSCs; group 2 will receive 1.0×10^6 cells/kg; with a total volume of 100 ml UCMSCs; group 3 will receive 2.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs. One month after each injection, the Data and Safety Monitoring Committee (DSMC) will comprehensively evaluate the results of the phased clinical research, and after determining the safety and feasibility of the research, the enrollment of the next phase will start. The subjects will be followed up on the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment. The main outcome measures are the severity and incidence of adverse events. The secondary outcome measures are RQLQ score, VAS score, serum inflammatory factor detection, nasal secretion inflammatory factor detection, nasal function test and nasal endoscopy, etc. In addition, the investigators will also monitor safety indicators such as blood routine, urine routine, liver and kidney function, immunological indicators, tumor markers, etc. At the end of the study, according to the data obtained, the clinical safety and feasibility of intravenous infusion of UCMSCs in the treatment of moderate to severe persistent AR will be evaluated, so as to provide drug dose basis for the next stage of clinical research.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yu Zhang, MD
- Phone Number: 83523 86 05356691999
- Email: superzhang013@163.com
Study Contact Backup
- Name: Peiwen Lian, PhD
- Phone Number: 82708 86 05356691999
- Email: lianpeiwen@qq.com
Study Locations
-
-
Shandong
-
Yantai, Shandong, China, 264000
- Recruiting
- Yantai Yuhuangding Hospital
-
Contact:
- Yu Zhang, MD
- Phone Number: 83523 86 05356691999
- Email: superzhang013@163.com
-
Contact:
- Peiwen Lian, PhD
- Phone Number: 82708 86 05356691999
- Email: lianpeiwen@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with moderate to severe persistent allergic rhinitis who meet the diagnostic criteria for allergic rhinitis (2015 Tianjin standard);
- The results of allergen examination showed that the allergen was a single allergy of dust mite;
- After more than 2 years of antihistamine, nasal glucocorticoid and other drug treatments, the curative effect is poor, and the symptoms seriously affect the patient's life;
- Age 18-60 years old;
- The patient refused to receive allergen-specific immunotherapy;
- The patient is willing to receive stem cell therapy and sign an informed consent.
Exclusion Criteria:
- The subject is accompanied by sinusitis, asthma and aspirin intolerance;
- The subjects suffer from severe primary heart, liver, lung, kidney and blood diseases;
- The subjects suffer from Malignant tumors;
- The subjects suffer from severe immune diseases;
- The subjects suffer from mental illness;
- Female subjects who are or are about to become pregnant, pregnant or breastfeeding;
- Patients who are participating in other clinical trials;
- In addition to the above conditions, there are other reasons why researchers believe that they are not suitable to participate in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose UCMSCs
|
Receive one course of treatment with a single injection : 0.5×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
|
Experimental: Moderate dose UCMSCs
|
Receive one course of treatment with a single injection : 1.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
|
Experimental: High dose UCMSCs
|
Receive one course of treatment with a single injection : 2.0×10^6 cells/kg, with a total volume of 100 ml UCMSCs;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity and incidence of adverse events (SIAE) on the day of treatment
Time Frame: Day 1 of treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
Day 1 of treatment
|
3rd day SIAE
Time Frame: 3 days after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
3 days after treatment
|
1 week SIAE
Time Frame: 1 week after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
1 week after treatment
|
1 month SIAE
Time Frame: 1 month after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
1 month after treatment
|
3 months SIAE
Time Frame: 3 months after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
3 months after treatment
|
6 months SIAE
Time Frame: 6 months after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
6 months after treatment
|
12 months SIAE
Time Frame: 12 months after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
12 months after treatment
|
24 months SIAE
Time Frame: 24 months after treatment
|
The assessment was conducted according to the Common Adverse Event Evaluation Standard 4.0 (NCI-CTCAE v4.0) jointly issued by the U.S. Department of Health and Human Services, the National Institutes of Health, and the National Cancer Institute.
|
24 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RQLQ score
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
The assessment of Rhinoconjunctivitis quality of life questionnaire (RQLQ) includes daily activities, sleep, non-rhino-conjunctivitis symptoms, rhinitis-related behaviors, nasal symptoms, eye symptoms, and emotional reactions. Each of the above aspect is composed of several measurements. A total of 28 measurements are individually scored from 0 to 6 points. A score of 0 indicates that the subject has not been affected by nose and eye symptoms in the past week, a score of 1 indicates that it is almost unaffected, a score of 2 indicates a minor influence, a score of 3 indicates a slight influence, a score of 4 indicates a moderate influence, and a score of 5 indicates a severe influence, a score of 6 indicates that it is extremely severely affected. In terms of daily activities, a score of 9 directly indicates that daily activity cannot be carried out due to nose and eye symptoms. |
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
VAS score
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Visual analogue scale (VAS) is used to evaluate the severity of nasal symptoms by patients or their guardians.
Visual line marks are made on the scale with a length of 10 cm.
The VAS score is calculated as 0 is asymptomatic (0 cm), and 10 is the most serious symptom (10 cm).
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Nasal function test
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Nasal expiratory nitric oxide (NO) test (NNO test), is a simple, noninvasive and convenient medical detection method, that can be used for the diagnosis, treatment and monitoring of nasal diseases such as rhinitis, sinusitis and nasal polyps.
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Nasal endoscopy
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
The normal nasal mucosa is light red, with smooth, moist and shiny surface. The nasal cavity and nasopharyngeal mucosa have no congestion, edema, dryness, ulcers, hemorrhage, vasodilatation and new organisms; no purulent secretions. The mucosa of allergic rhinitis is pale, edematous or lavender, and the discharge is watery. |
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
U-HCG
Time Frame: The day of enrollment screening, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
The U-HCG test detects levels of hCG in the urine, positive result indicate pregnacy.
|
The day of enrollment screening, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interferon γ (IFN-γ)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interferon γ (IFN-γ) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interferon α (IFN-α)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interferon α (IFN-α) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 1β (IL-1β)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 1β (IL-1β) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 2 (IL-2)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 2 (IL-2) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 4 (IL-4)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 4 (IL-4) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 5 (IL-5)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 5 (IL-5) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 6 (IL-6)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 6 (IL-6) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 8 (IL-8)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 8 (IL-8) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 10 (IL-10)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 10 (IL-10) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 12P70 (IL-12P70)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 12P70 (IL-12P70) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Interleukin 17A (IL-17A)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 17A (IL-17A) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of Serum Tumor necrosis factor-α(TNF-α)
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Tumor necrosis factor-α(TNF-α) in the serum;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interferon γ (IFN-γ) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interferon γ (IFN-γ) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interferon α (IFN-α) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interferon α (IFN-α) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 1β (IL-1β) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interferon α (IFN-α) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 2 (IL-2) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 2 (IL-2) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 4 (IL-4) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 4 (IL-4) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 5 (IL-5) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 5 (IL-5) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 6 (IL-6) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 6 (IL-6) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 8 (IL-8) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 8 (IL-8) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 10 (IL-10) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 10 (IL-10) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Detection of inflammatory factor Tumor necrosis factor-α(TNF-α) in nasal secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To test level of inflammatory factor Tumor necrosis factor-α(TNF-α) in nasal secretions;
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood routine
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Include hemoglobin determination, red blood cell count, white blood cell count white blood cell classification.
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Urine routine
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Include urine color, potential of hydrogen (pH) value of urine, protein qualitative and microscopic determination of urine sediment count.
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Liver and kidney function
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
A group of laboratory tests that helps detect problems or disorders in the liver or kidney.
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Immunological indicators
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Cell counts of T cells and their subtypes in peripheral blood
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Tumor markers
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Carcinoembryonic antigen(CEA) ,Alpha-FetoProtein(AFP)
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Total Protein Concentration of Nasal Secretions
Time Frame: The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
To determinate the total protein concentration of nasal secretions.
|
The day of enrollment screening, the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xicheng Song, MD, Yantai Yuhuangding Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
Clinical Trials on Low dose UCMSCs
-
Yantai Yuhuangding HospitalRecruiting
-
South China Research Center for Stem Cell and Regenerative...Guangzhou Panyu Central HospitalUnknownFracture | Bone Nonunion
-
China Medical University HospitalUnknownBronchopulmonary Dysplasia | Extremely Premature Infants | Severe BPD That Conventional Therapies Has Failed | No Severe Congenital Anomalies | no Severe IVH Neither Cystic PVLTaiwan
-
Joshua M HareThe Marcus FoundationTerminatedMetabolic Syndrome | Endothelial Dysfunction | Chronic InflammationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...Peking Union Medical College HospitalNot yet recruitingPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
South China Research Center for Stem Cell and Regenerative...Third Affiliated Hospital, Sun Yat-Sen University; Guangzhou General Hospital...UnknownAlzheimer's DiseaseChina